Simos Simeonidis analyst

Currently out of the existing stock ratings of Simos Simeonidis, 36 are a BUY (78.26%), 10 are a HOLD (21.74%).

Simos Simeonidis

Work Performance Price Targets & Ratings Chart

Analyst Simos Simeonidis, has had 70.17% of price targets met with an average potential upside of 34.98%, reached in 652 days on average. Previously, Simos Simeonidis worked at RBC.

Simos Simeonidis has documented 85 price targets and ratings displayed on 12 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on INCY, yte at 04-Apr-2017.

Wall Street Analyst Simos Simeonidis

Analyst best performing recommendations are on DVAX (DYNAVAX TECHNOLOGIES).
The best stock recommendation documented was for DVAX (DYNAVAX TECHNOLOGIES) on 4/27/2016. The price target of $17 was fulfilled within 2 days with a profit of $1.53 (8.26%), with a performance score of 41.28.

Average potential price target upside

ALXN Alexion Pharmaceuticals DVAX Dynavax Technologies IMGN ImmunoGen INCY yte OREX Orexigen Therapeutics PBYI Puma Biotechnology VVUS VIVUS ZFGN Zafgen PTCT PTC Therapeutics LRMR Larimar Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 28-Jul-2017

$205

5 years 6 months 16 days ago
(05-May-2021)

3/5 (60%)

$35.09 (20.65%)

938

Hold Since 03-May-2021

$173

$156

5 years 6 months 18 days ago
(03-May-2021)

18/29 (62.07%)

$2.73 (1.60%)

667

Buy Since 08-Feb-2018

$166

$179

5 years 9 months 17 days ago
(04-Feb-2021)

21/21 (100%)

$10.41 (6.69%)

711

Hold Since 04-Feb-2021

$190

$194

5 years 9 months 17 days ago
(04-Feb-2021)

13/15 (86.67%)

$34.41 (22.12%)

458

Buy Since 06-Sep-2019

$175

$165

5 years 9 months 17 days ago
(04-Feb-2021)

3/3 (100%)

$19.41 (12.48%)

397

Show more analysts

Stocks Simos Simeonidis covered previously. Scores are shown for active stocks only.

SRPT Sarepta Therapeutics

Please expand the browser size to see the chart

✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?